Clinical trialNCT02287467CompletedPhase 3Interventional

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment329Influenza AInfluenza B

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Eduardo Fernández-Cruz, MD, PhD
Hospital General Universitario Gregorio Marañon
Study Chair
clinicaltrials.gov ↗
Norman P. Markowitz, MD
The Henry Ford Hospital
Study Chair
clinicaltrials.gov ↗
Richard T. Davey, Jr., MD
National Institute of Allergy and Infectious Diseases (NIAID)
Study ChairKOL profile →
clinicaltrials.gov ↗
Sarah L. Pett, MD, MBBS, DTM, MRCP (UK)
University College, London
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Westmead Hospital
Sydney, Australia

Denmark

Odense University Hospital
Odense, Denmark

United Kingdom

St James'S University Hospital
Leeds, United Kingdom
Churchill Hospital
Oxford, United Kingdom

United States

Ucsd Antiviral Research Center (a Vrc)
San Diego, California, United States
Denver Public Health
Denver, Colorado, United States
University of Illinois
Chicago, Illinois, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Henry Ford Hospital
Detroit, Michigan, United States
Minneapolis Va Medical Center
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Cooper University Hospital
Camden, New Jersey, United States
Cornell Crs
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Duke University
Durham, North Carolina, United States
Case Western Reserve University
Cleveland, Ohio, United States
Ohio State University (osu) Wexner Medical Center
Columbus, Ohio, United States
Miami Valley Hospital
Dayton, Ohio, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Ut Southwestern Medical Center
Dallas, Texas, United States
West Virginia University
Morgantown, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intravenous hyperimmune immunoglobulinPlacebo for IVIG

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2015
Primary completion: 7 Jun 2018
Completion: 7 Jun 2018
Last update posted: 14 Nov 2019
Registered enrollment: 329
Registry id: NCT02287467

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.